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Evidence, Policy, and E-Cigarettes
To the Editor: In their Perspective article in the 
April 7 issue,1 Green et al. argue that the English 
approach to e-cigarettes could reframe the de-
bate on these products. They cite our article,2 im-
plying that we were concerned about only one of 
the many studies in the Public Health England 
(PHE) review. That study was only one of our 
concerns, being the only source for the widely 
cited “95% safer” claim, especially given questions 
about conflicts of interest.3 We also discussed 
other evidence, some not quoted in the review, 
that raised serious questions about the safety of 
these products.4 Green et al. disregard the fact 
that harm reduction is only one element of a 
comprehensive drug strategy that, as in the suc-
cessful Australian model, also encompasses re-
duction of demand and supply. It is misleading to 
suggest that there is a consensus on e-cigarettes 
in England, given that many members of the 
health community have continuing reservations.5 
If we are to reframe the debate, maybe we should 
instead look to Australia, where adult smoking 
rates are now under 13%, without e-cigarettes.
Martin McKee, M.D., D.Sc.
London School of Hygiene and Tropical Medicine 
London, United Kingdom
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To the Editor: Green, Bayer, and Fairchild 
misrepresent the position of the Campaign for 
Tobacco-Free Kids on e-cigarettes. From the be-
ginning, our organization has called for the 
Food and Drug Administration (FDA) to regulate 
e-cigarettes. We have repeatedly stated that it is 
possible that e-cigarettes could benefit public 
health if they are properly regulated, shown to be 
effective at helping smokers quit smoking regular 
cigarettes completely, and responsibly marketed to 
smokers who cannot or will not otherwise quit.1,2 
However, we have also raised legitimate concerns 
about the large and rapid increase in the use of 
e-cigarettes by young people in the United States 
and the irresponsible marketing of these prod-
ucts with the use of tactics similar to those long 
used to make regular cigarettes appealing to 
children.3 It is not by any definition “absolutist” 
to call for FDA regulation of e-cigarettes. Effec-
tive regulation by the FDA is critical to minimiz-
ing the risks posed by e-cigarettes and maximizing 
the potential benefits.
Matthew L. Myers, J.D.
Campaign for Tobacco-Free Kids 
Washington, DC
No potential conflict of interest relevant to this letter was re-
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The authors reply: We agree with Myers re-
garding the need to regulate electronic cigarettes 
sensibly to protect public health. Rules and poli-
cies should encourage smokers to switch to lower-
risk tobacco products while also preventing non-
smokers, particularly young people, from picking 
up these devices. Nevertheless, our intention was 
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to contrast the broad public stances toward e-ciga-
rettes held by major antitobacco organizations in 
the United Kingdom and the United States. In the 
United States, many advocacy organizations claim 
to support tobacco harm reduction but effectively 
endorse prohibition by regulation. Although Myers 
and the Campaign for Tobacco-Free Kids may be-
lieve in the potential for e-cigarettes to benefit 
public health if regulated properly, their messag-
ing does not support the use of e-cigarettes for 
harm reduction in the ways that the U.K. Action on 
Smoking and Health (ASH) does. The Campaign 
focuses primarily on the prevention of hypotheti-
cal risks to nonsmoking children, whereas ASH’s 
emphasis is on improving the health of smokers 
who cannot or will not quit smoking cigarettes, 
which kill half of all long-term users, who lose 
more than 20 years of life, on average.
In response to McKee: we did not suggest that 
harm reduction is the only strategy to combat 
tobacco. Two of us (Bayer and Fairchild) have 
written extensively on laws, taxes, and campaigns 
to reduce the burden of tobacco. The focus in 
our recent article was on tobacco harm reduc-
tion, which should, of course, be implemented 
as part of a comprehensive drug strategy. McKee 
is correct in pointing out that there is not com-
plete consensus in the United Kingdom regard-
ing e-cigarettes, as we noted in our article. But 
what we underscored and what makes the United 
Kingdom exceptional is that many leading orga-
nizations support e-cigarettes for harm reduc-
tion. In fact, 12 prominent British organizations 
signed a press release supporting the PHE report. 
These organizations included the British Lung 
Foundation, Cancer Research UK, Faculty of Pub-
lic Health, and the Royal College of Physicians.1
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